Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.

The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease

Open access

Abstract

The beta‐site amyloid precursor protein cleaving enzyme‐1 (BACE‐1) initiates the generation of amyloid‐β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti‐Aβ therapies in dementia stages suggest that treatment has to start in the early, asymptomatic disease states. The BACE‐1 inhibitor CNP520 has a selectivity, pharmacodynamics, and distribution profile suitable for AD prevention studies. CNP520 reduced brain and cerebrospinal fluid (CSF) Aβ in rats and dogs, and Aβ plaque deposition in APP‐transgenic mice. Animal toxicology studies of CNP520 demonstrated sufficient safety margins, with no signs of hair depigmentation, retina degeneration, liver toxicity, or cardiovascular effects. In healthy adults ≥ 60 years old, treatment with CNP520 was safe and well tolerated and resulted in robust and dose‐dependent Aβ reduction in the cerebrospinal fluid. Thus, long‐term, pivotal studies with CNP520 have been initiated in the Generation Program. Alzheimer's disease (AD) is a chronic neurodegenerative disorder with increasing incidence in the aging societies, but without any disease‐modifying treatment. Deposition of toxic forms of the protein Aβ in the brain is pathologic. Treatment with a BACE‐1 inhibitor may prevent Aβ deposition. Alzheimer's disease (AD) is a chronic neurodegenerative disorder with increasing incidence in the aging societies, but without any disease‐modifying treatment. Deposition of toxic forms of the protein Aβ in the brain is pathologic. Treatment with a BACE‐1 inhibitor may prevent Aβ deposition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201809316

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Design of CNP520 AMolecular structure.BX‐ray structure of CNP520 bound to the BACE‐1 active site (resolution: 1.35 Å), with binding pockets S1 (filled by P1) and S3 (filled by P3) and catalytic residues Asp32 and Asp228.CBlood and brain tissue levels of CNP520 in the rat after a 30 μmol/kg (15.4 mg/kg) oral dose. Shown are unbound fraction (main graph) and total levels (insert) of CNP520 in the blood and brain, using values for rat plasma protein binding of 97.8% and unspecific binding to brain homogenate of 99%. Values are mean ± SD, with n = 5 per time point.DStructure of the aminopyridine generated by metabolic cleavage of the amide bond in CNP520.
Figure 1 Design of CNP520 AMolecular structure.BX‐ray structure of CNP520 bound to the BACE‐1 active site (resolution: 1.35 Å), with binding pockets S1 (filled by P1) and S3 (filled by P3) and catalytic residues Asp32 and Asp228.CBlood and brain tissue levels of CNP520 in the rat after a 30 μmol/kg (15.4 mg/kg) oral dose. Shown are unbound fraction (main graph) and total levels (insert) of CNP520 in the blood and brain, using values for rat plasma protein binding of 97.8% and unspecific binding to brain homogenate of 99%. Values are mean ± SD, with n = 5 per time point.DStructure of the aminopyridine generated by metabolic cleavage of the amide bond in CNP520.CC BY · PubMed Central
Figure 2 CNP520 treatment of male C57/BL6 mice for 8 weeks did not cause hair depigmentation ASubjective assessment of hair depigmentation (score 0–5, with 0 = completely black and 5 = completely white) at two doses of either CNP520 or the BACE‐1/‐2 inhibitor NB‐360 (Shimshek et al, 2016; mean ± SEM, n = 8/group), statistical comparisons were made for every scoring day, versus vehicle using Kruskal–Wallis with Dunn's post hoc test.BSummary of doses, steady‐state effects on Aβ40 in brain (% compared to vehicle‐treated mice) and the ratios between total skin concentrations of CNP520 and NB‐360 and their respective IC50 values for inhibition of BACE‐2 in vitro.
Figure 2 CNP520 treatment of male C57/BL6 mice for 8 weeks did not cause hair depigmentation ASubjective assessment of hair depigmentation (score 0–5, with 0 = completely black and 5 = completely white) at two doses of either CNP520 or the BACE‐1/‐2 inhibitor NB‐360 (Shimshek et al, 2016; mean ± SEM, n = 8/group), statistical comparisons were made for every scoring day, versus vehicle using Kruskal–Wallis with Dunn's post hoc test.BSummary of doses, steady‐state effects on Aβ40 in brain (% compared to vehicle‐treated mice) and the ratios between total skin concentrations of CNP520 and NB‐360 and their respective IC50 values for inhibition of BACE‐2 in vitro.CC BY · PubMed Central
Figure EV1 Assessment of intracerebral micro‐hemorrhages in APP23‐transgenic mice, dosed orally with CNP520 at 30 mg/kg for 3 months AAssessment of brain lesion volume by longitudinal magnetic resonance imaging. For description of the method, see Beckmann et al (2016). White bars show the APP23‐typical age‐dependent increase in lesion volume, and black bars show the effect of CNP520. The antibody β1 serves as positive control and shows enhancement of lesion volume over time. ANOVA test with random effects was applied. Shown is average ± SEM; for n numbers, see table in panel (B). Non‐underlined P‐values: comparison to baseline, only significant differences are shown. Underlined P‐values: significant differences between treatment groups at the given time point.BResults of histopathological staining using Perl's staining and H&E staining. APP23 (21 months of age) was sacrificed; four brain sections were processed and stained with hematoxylin and eosin (H&E) and Prussian blue for hemosiderin deposits. Levels 2, 3, and 4, and one additional slide at hypothalamus level (level 2’). Brain sections stained with hematoxylin and eosin and with Perl's Prussian blue were examined under a light microscope. The distribution, size, and staining intensity of hemosiderin deposits in Perl's Prussian blue‐stained sections were assessed and recorded. Table lists the number of animals affected, and the percentage.
Figure EV1 Assessment of intracerebral micro‐hemorrhages in APP23‐transgenic mice, dosed orally with CNP520 at 30 mg/kg for 3 months AAssessment of brain lesion volume by longitudinal magnetic resonance imaging. For description of the method, see Beckmann et al (2016). White bars show the APP23‐typical age‐dependent increase in lesion volume, and black bars show the effect of CNP520. The antibody β1 serves as positive control and shows enhancement of lesion volume over time. ANOVA test with random effects was applied. Shown is average ± SEM; for n numbers, see table in panel (B). Non‐underlined P‐values: comparison to baseline, only significant differences are shown. Underlined P‐values: significant differences between treatment groups at the given time point.BResults of histopathological staining using Perl's staining and H&E staining. APP23 (21 months of age) was sacrificed; four brain sections were processed and stained with hematoxylin and eosin (H&E) and Prussian blue for hemosiderin deposits. Levels 2, 3, and 4, and one additional slide at hypothalamus level (level 2’). Brain sections stained with hematoxylin and eosin and with Perl's Prussian blue were examined under a light microscope. The distribution, size, and staining intensity of hemosiderin deposits in Perl's Prussian blue‐stained sections were assessed and recorded. Table lists the number of animals affected, and the percentage.CC BY · PubMed Central
Figure 3 Oral administration of CNP520 to rats and dogs ADoses from 1.5 mg/kg (3 μmol/kg) to 51.3 mg/kg (100 μmol/kg) were given by oral gavage to rats (n = 5 per dose); animals were killed 4 h later for determination of Aβ40 in brain tissue. Values are mean ± SEM as determined by ANOVA (GraphPad Prism).BTime‐dependent reduction of Aβ40 in rat brain and CSF after a single 15.4 mg/kg (30 μmol/kg) oral dose of CNP520 (mean ± SD, n = 5).CCNP520 levels in dog blood and CSF, following a 3.1 mg/kg (6 μmol/kg) oral dose (mean ± SD, n = 4).DTime‐dependent reduction of Aβ40 and 42 in dog CSF, after a 3.1 mg/kg oral CNP520 dose (mean ± SD, n = 4).
Figure 3 Oral administration of CNP520 to rats and dogs ADoses from 1.5 mg/kg (3 μmol/kg) to 51.3 mg/kg (100 μmol/kg) were given by oral gavage to rats (n = 5 per dose); animals were killed 4 h later for determination of Aβ40 in brain tissue. Values are mean ± SEM as determined by ANOVA (GraphPad Prism).BTime‐dependent reduction of Aβ40 in rat brain and CSF after a single 15.4 mg/kg (30 μmol/kg) oral dose of CNP520 (mean ± SD, n = 5).CCNP520 levels in dog blood and CSF, following a 3.1 mg/kg (6 μmol/kg) oral dose (mean ± SD, n = 4).DTime‐dependent reduction of Aβ40 and 42 in dog CSF, after a 3.1 mg/kg oral CNP520 dose (mean ± SD, n = 4).CC BY · PubMed Central
Figure 4 Chronic therapeutic treatment of APP23 mice with CNP520 Male APP23 mice (age at baseline: 12–14 months old) were dosed with CNP520 in food pellets for 6 months: Low dose 0.03 g CNP520/kg food, corresponding to a daily oral dose of 4 mg/kg; high dose 0.3 g/kg food, corresponding to a daily oral dose of 40 mg/kg. ACNP520 levels in blood and cerebellum.BTotal cortical plaque area (normalized to total sample area (*10−2), stained with antibody NT‐12.CFormic acid‐soluble Aβ40 in forebrain.DFormic acid‐soluble Aβ42 in forebrain.EDouble‐immunofluorescence‐stained brain sections with NT12 (against amyloid‐β, green) and Iba1 (against microglia, red) or GFAP (astrocytes, red) for the different treatment groups as indicated. Scale bar: 500 μm.FQuantification of total Iba1‐positive microglia (normalized to total area (*10−2), only a subset of samples analyzed.GQuantification of total GFAP‐positive astrocyte area (normalized to total area (*10−2).Data information: (A, B, C, D, and G) Baseline, n = 10, vehicle, n = 17, CNP520 low dose, n = 14, CNP520 high dose, n = 13. (F) All groups n = 7. Date are mean ± SEM. Data were analyzed with one way ANOVA and Dunnett’s multiple comparison test.
Figure 4 Chronic therapeutic treatment of APP23 mice with CNP520 Male APP23 mice (age at baseline: 12–14 months old) were dosed with CNP520 in food pellets for 6 months: Low dose 0.03 g CNP520/kg food, corresponding to a daily oral dose of 4 mg/kg; high dose 0.3 g/kg food, corresponding to a daily oral dose of 40 mg/kg. ACNP520 levels in blood and cerebellum.BTotal cortical plaque area (normalized to total sample area (*10−2), stained with antibody NT‐12.CFormic acid‐soluble Aβ40 in forebrain.DFormic acid‐soluble Aβ42 in forebrain.EDouble‐immunofluorescence‐stained brain sections with NT12 (against amyloid‐β, green) and Iba1 (against microglia, red) or GFAP (astrocytes, red) for the different treatment groups as indicated. Scale bar: 500 μm.FQuantification of total Iba1‐positive microglia (normalized to total area (*10−2), only a subset of samples analyzed.GQuantification of total GFAP‐positive astrocyte area (normalized to total area (*10−2).Data information: (A, B, C, D, and G) Baseline, n = 10, vehicle, n = 17, CNP520 low dose, n = 14, CNP520 high dose, n = 13. (F) All groups n = 7. Date are mean ± SEM. Data were analyzed with one way ANOVA and Dunnett’s multiple comparison test.CC BY · PubMed Central
Figure EV2 Effect of CNP520 on microglia and astrocytes in APP23 mice Mice were dosed with CNP520 in food pellets. Low dose: 0.03 g CNP520/kg food, exposure corresponds to a daily oral dose of 4 mg/kg. High dose: 0.3 g/kg food, exposure corresponds to a daily oral dose of 40 mg/kg. Half brains were embedded in paraffin, cut, and stained with Iba1 antibody for activated microglia and with GFAP antibody for astrocytes. APlaque‐associated area of Iba1‐positive cells.BNon‐plaque‐associated Iba1‐positive cells.CCorrelation of normalized plaque‐associated Iba1 area with normalized plaque area. Shown is average ± SEM; dashed lines show the 95% confidence interval.DCorrelation of normalized non‐plaque‐associated area with normalized plaque area. Shown is average ± SEM; dashed lines show the 95% confidence interval.EPlaque‐associated area of GFAP‐positive cells.FNon‐plaque‐associated GFAP‐positive cells.GCorrelation of normalized plaque‐associated GFAP‐positive area with normalized plaque area. Shown is average ± SEM; dashed lines show the 95% confidence interval.HCorrelation of normalized non‐plaque‐associated area with normalized plaque area. Shown is average ± SEM; dashed lines show the 95% confidence interval.Data information: (A and B) n = 7/group. (E and F) Baseline, n = 10, vehicle: n = 17, CNP520 low dose: n = 14, CNP520 high dose: n = 13. One way ANOVA with Dunnett's multiple comparison test was used in panels (A, B, E, and F).
Figure EV2 Effect of CNP520 on microglia and astrocytes in APP23 mice Mice were dosed with CNP520 in food pellets. Low dose: 0.03 g CNP520/kg food, exposure corresponds to a daily oral dose of 4 mg/kg. High dose: 0.3 g/kg food, exposure corresponds to a daily oral dose of 40 mg/kg. Half brains were embedded in paraffin, cut, and stained with Iba1 antibody for activated microglia and with GFAP antibody for astrocytes. APlaque‐associated area of Iba1‐positive cells.BNon‐plaque‐associated Iba1‐positive cells.CCorrelation of normalized plaque‐associated Iba1 area with normalized plaque area. Shown is average ± SEM; dashed lines show the 95% confidence interval.DCorrelation of normalized non‐plaque‐associated area with normalized plaque area. Shown is average ± SEM; dashed lines show the 95% confidence interval.EPlaque‐associated area of GFAP‐positive cells.FNon‐plaque‐associated GFAP‐positive cells.GCorrelation of normalized plaque‐associated GFAP‐positive area with normalized plaque area. Shown is average ± SEM; dashed lines show the 95% confidence interval.HCorrelation of normalized non‐plaque‐associated area with normalized plaque area. Shown is average ± SEM; dashed lines show the 95% confidence interval.Data information: (A and B) n = 7/group. (E and F) Baseline, n = 10, vehicle: n = 17, CNP520 low dose: n = 14, CNP520 high dose: n = 13. One way ANOVA with Dunnett's multiple comparison test was used in panels (A, B, E, and F).CC BY · PubMed Central
Figure 5 Pharmacokinetics of CNP520 in adults ≥ 60 years of age AMean plasma concentration versus time profiles after single dose.BMean plasma concentration profiles for 91 days of dosing and post‐dose concentrations up to day 121.CTime versus CSF concentration profiles after single dose of CNP520 (mean ± SEM, n = 6–8).DDose–CSF concentration profiles after 3 months of dosing (mean ± SEM, n = 22–24).
Figure 5 Pharmacokinetics of CNP520 in adults ≥ 60 years of age AMean plasma concentration versus time profiles after single dose.BMean plasma concentration profiles for 91 days of dosing and post‐dose concentrations up to day 121.CTime versus CSF concentration profiles after single dose of CNP520 (mean ± SEM, n = 6–8).DDose–CSF concentration profiles after 3 months of dosing (mean ± SEM, n = 22–24).CC BY · PubMed Central
Figure 6 Effects of CNP520 administration on major APP metabolites in the CSF of healthy study participants ≥ 60 years of age A–CCSF was sampled via a lumbar catheter at time points from 2 h pre‐ to 34 h post‐administration of a single dose of CNP520 (mean ± SEM, n = 6–8). (A) Changes in Aβ40 relative to baseline values. (B) Changes in sAPPβ relative to baseline values. (C) Changes in sAPPα relative to baseline values.DDose–response of Aβ40 to CNP520 relative to baseline Aβ40 levels after 2 weeks of dosing. CNP520 was administered daily for 14 days; CSF was sampled via a lumbar catheter 2 h before dosing and 24 h after the last dose (mean ± SD, n = 8 in treatment groups, n = 16 in placebo group).
Figure 6 Effects of CNP520 administration on major APP metabolites in the CSF of healthy study participants ≥ 60 years of age A–CCSF was sampled via a lumbar catheter at time points from 2 h pre‐ to 34 h post‐administration of a single dose of CNP520 (mean ± SEM, n = 6–8). (A) Changes in Aβ40 relative to baseline values. (B) Changes in sAPPβ relative to baseline values. (C) Changes in sAPPα relative to baseline values.DDose–response of Aβ40 to CNP520 relative to baseline Aβ40 levels after 2 weeks of dosing. CNP520 was administered daily for 14 days; CSF was sampled via a lumbar catheter 2 h before dosing and 24 h after the last dose (mean ± SD, n = 8 in treatment groups, n = 16 in placebo group).CC BY · PubMed Central
Figure 7 Effects of CNP520 administration for 3 months on Aβ40 in the CSF of healthy study participants ≥ 60 years of age AChanges of Aβ40 relative from baseline values up to 3 months of daily dosing. Shown are means ± SD, n = 21–25 for pre‐dose and day 91, and n = 2–7 for the intermediate time points.BDose–response for CSF Aβ40 at day 91 (24 h after last dose) and individual percent change from baseline, shown as mean and 95% confidence interval, n = 21–25 per treatment group.
Figure 7 Effects of CNP520 administration for 3 months on Aβ40 in the CSF of healthy study participants ≥ 60 years of age AChanges of Aβ40 relative from baseline values up to 3 months of daily dosing. Shown are means ± SD, n = 21–25 for pre‐dose and day 91, and n = 2–7 for the intermediate time points.BDose–response for CSF Aβ40 at day 91 (24 h after last dose) and individual percent change from baseline, shown as mean and 95% confidence interval, n = 21–25 per treatment group.CC BY · PubMed Central
Figure 8 Effect of APOE genotype and baseline Aβ42/40 ratio on response to CNP520 treatment AMouse forebrain Aβ40 levels in homozygous male and female APOE4‐TR mice with and without CNP520 treatment, 4 h after dosing, shown is mean ± SEM, n = 6/group. Data were analyzed with one way ANOVA and Dunnett's multiple comparison test.BDistribution of APOE4 genotypes in the Phase IIa study versus their baseline Aβ42/40 ratios. The dashed line at Aβ42/40 ratio of 0.09 represents a cutoff, which separates a normal ratio from an abnormally low ratio.CComparison of CSF Aβ40 reduction in APOE4 non‐carriers and APOE4 carriers (mean ± SD).DComparison of CSFAβ40 reduction in participants with Aβ42/40 ≥ 0.09 and Aβ42/40 < 0.09 (mean ± SD).EComparison of Aβ42/40 ratio at baseline and at day 91 for all participants in the placebo, 35 mg, and 85‐mg dose group (mean ± SD, n = 25/group).FChange of Aβ42/40 ratio for all participants with Aβ42/40 ≤ 0.09 at baseline; bars represent mean ± SD. Full circles: APOE4 carrier, open circles: APOE4 non‐carrier. Data were analyzed with one way ANOVA and Dunnett's multiple comparison test.
Figure 8 Effect of APOE genotype and baseline Aβ42/40 ratio on response to CNP520 treatment AMouse forebrain Aβ40 levels in homozygous male and female APOE4‐TR mice with and without CNP520 treatment, 4 h after dosing, shown is mean ± SEM, n = 6/group. Data were analyzed with one way ANOVA and Dunnett's multiple comparison test.BDistribution of APOE4 genotypes in the Phase IIa study versus their baseline Aβ42/40 ratios. The dashed line at Aβ42/40 ratio of 0.09 represents a cutoff, which separates a normal ratio from an abnormally low ratio.CComparison of CSF Aβ40 reduction in APOE4 non‐carriers and APOE4 carriers (mean ± SD).DComparison of CSFAβ40 reduction in participants with Aβ42/40 ≥ 0.09 and Aβ42/40 < 0.09 (mean ± SD).EComparison of Aβ42/40 ratio at baseline and at day 91 for all participants in the placebo, 35 mg, and 85‐mg dose group (mean ± SD, n = 25/group).FChange of Aβ42/40 ratio for all participants with Aβ42/40 ≤ 0.09 at baseline; bars represent mean ± SD. Full circles: APOE4 carrier, open circles: APOE4 non‐carrier. Data were analyzed with one way ANOVA and Dunnett's multiple comparison test.CC BY · PubMed Central
Figure EV3 Free (unbound) CNP520 plasma exposure in humans, relative to the in vitro IC50 value for hERG and BACE‐2 inhibition Shown are maximum free CNP520 levels after a single dose, in humans and in dogs, and steady‐state exposure after 3‐month dosing in human and 9‐month dosing in dogs. Shown is mean ± coefficient of variation. Human single dose: n = 8/dose, human steady state: n = 25/dose, dog single dose: n = 4, dog steady state: n = 5.
Figure EV3 Free (unbound) CNP520 plasma exposure in humans, relative to the in vitro IC50 value for hERG and BACE‐2 inhibition Shown are maximum free CNP520 levels after a single dose, in humans and in dogs, and steady‐state exposure after 3‐month dosing in human and 9‐month dosing in dogs. Shown is mean ± coefficient of variation. Human single dose: n = 8/dose, human steady state: n = 25/dose, dog single dose: n = 4, dog steady state: n = 5.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

See all 188

Metadata

Authors
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., Rueeger, H., Tintelnot‐Blomley, M., Staufenbiel, M., Shimshek, D. R., Perrot, L., Frieauff, W., Dubost, V., Schiller, H., Vogg, B., Beltz, K., Avrameas, A., Kretz, S., Pezous, N., Rondeau, J., Beckmann, N., Hartmann, A., Vormfelde, S., David, O. J., Galli, B., Ramos, R., Graf, A., & Lopez Lopez, C.
Affiliations
Novartis (Switzerland) (CH)
Corresponding author
Neumann, Ulf
Venue
EMBO Molecular Medicine
Published
2018-09-17
Volume
10
Issue
11
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2890206141
Cited by
177
References
65
Citations by year
2026: 7 · 2025: 23 · 2024: 34 · 2023: 20 · 2022: 24 · 2021: 23 · 2020: 23 · 2019: 19 · 2018: 3
FWCI
12.18
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DORA PSI (Paul Scherrer Institute) (submittedVersion, other-oa)
  • Minerva Access (University of Melbourne) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Novartis Pharma AG, Basel, Switzerland
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
BACE1 inhibitors, Alzheimer's disease, amyloid-beta, amyloid hypothesis, disease prevention, early Alzheimer's disease, cerebrospinal fluid amyloid-beta, APP transgenic mice, veterinary toxicology, drug safety, disease-modifying therapy
MeSH terms
Alzheimer Disease, Animals, Astrocytes, Brain, Cathepsin D, Cerebral Hemorrhage, Female, Humans, Inflammation, Male, Mice, Inbred C57BL, Mice, Transgenic, Oxazines, Hominidae, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Microglia, Amyloid Precursor Protein Secretases, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease. https://app.cochat.ai/papers/10.15252/emmm.201809316
The paper
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., Rueeger, H., Tintelnot‐Blomley, M., Staufenbiel, M., Shimshek, D. R., Perrot, L., Frieauff, W., Dubost, V., Schiller, H., Vogg, B., . . . Lopez Lopez, C. (2018). The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201809316

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.